Cargando…

Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?

OBJECTIVE: To compare pneumonic-type invasive mucinous adenocarcinoma (pIMA) confined to a single lobe with clinical T2, T3, and T4 stage lung cancer without pathological node metastasis regarding survival after curative surgery and to identify prognostic factors for pIMA. MATERIALS AND METHODS: Fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Wooil, Lee, Sang Min, Lee, Jung Bok, Seo, Joon Beom, Kim, Hong Kwan, Kim, Jhingook, Lee, Ho Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876658/
https://www.ncbi.nlm.nih.gov/pubmed/35213098
http://dx.doi.org/10.3348/kjr.2021.0465
_version_ 1784658225673535488
author Kim, Wooil
Lee, Sang Min
Lee, Jung Bok
Seo, Joon Beom
Kim, Hong Kwan
Kim, Jhingook
Lee, Ho Yun
author_facet Kim, Wooil
Lee, Sang Min
Lee, Jung Bok
Seo, Joon Beom
Kim, Hong Kwan
Kim, Jhingook
Lee, Ho Yun
author_sort Kim, Wooil
collection PubMed
description OBJECTIVE: To compare pneumonic-type invasive mucinous adenocarcinoma (pIMA) confined to a single lobe with clinical T2, T3, and T4 stage lung cancer without pathological node metastasis regarding survival after curative surgery and to identify prognostic factors for pIMA. MATERIALS AND METHODS: From January 2010 to December 2017, 41 patients (15 male; mean age ± standard deviation, 66.0 ± 9.9 years) who had pIMA confined to a single lobe on computed tomography (CT) and underwent curative surgery were identified in two tertiary hospitals. Three hundred and thirteen patients (222 male; 66.3 ± 9.4 years) who had non-small cell lung cancer (NSCLC) without pathological node metastasis and underwent curative surgery in one participating institution formed a reference group. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Cox proportional hazard regression analysis was performed to identify factors associated with the survival of patients with pIMA. RESULTS: The 5-year RFS and OS rates in patients with pIMA were 33.1% and 56.0%, respectively, compared with 74.3% and 91%, 64.3% and 71.8%, and 46.9% and 49.5% for patients with clinical stage T2, T3, and T4 NSCLC in the reference group, respectively. The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 NSCLC and significantly worse than that of patients with clinical stage T3 NSCLC (p = 0.012). The differences in OS between patients with pIMA and those with clinical stage T3 or T4 NSCLC were not significant (p = 0.11 and p = 0.37, respectively). In patients with pIMA, the presence of separate nodules was a significant factor associated with poor RFS and OS {unadjusted hazard ratio (HR), 4.66 (95% confidence interval [CI], 1.95–11.11), p < 0.001 for RFS; adjusted HR, 4.53 (95% CI, 1.59–12.89), p = 0.005 for OS}. CONCLUSION: The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 lung cancer. Separate nodules on CT were associated with poor RFS and OS in patients with pIMA.
format Online
Article
Text
id pubmed-8876658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Radiology
record_format MEDLINE/PubMed
spelling pubmed-88766582022-03-09 Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3? Kim, Wooil Lee, Sang Min Lee, Jung Bok Seo, Joon Beom Kim, Hong Kwan Kim, Jhingook Lee, Ho Yun Korean J Radiol Thoracic Imaging OBJECTIVE: To compare pneumonic-type invasive mucinous adenocarcinoma (pIMA) confined to a single lobe with clinical T2, T3, and T4 stage lung cancer without pathological node metastasis regarding survival after curative surgery and to identify prognostic factors for pIMA. MATERIALS AND METHODS: From January 2010 to December 2017, 41 patients (15 male; mean age ± standard deviation, 66.0 ± 9.9 years) who had pIMA confined to a single lobe on computed tomography (CT) and underwent curative surgery were identified in two tertiary hospitals. Three hundred and thirteen patients (222 male; 66.3 ± 9.4 years) who had non-small cell lung cancer (NSCLC) without pathological node metastasis and underwent curative surgery in one participating institution formed a reference group. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Cox proportional hazard regression analysis was performed to identify factors associated with the survival of patients with pIMA. RESULTS: The 5-year RFS and OS rates in patients with pIMA were 33.1% and 56.0%, respectively, compared with 74.3% and 91%, 64.3% and 71.8%, and 46.9% and 49.5% for patients with clinical stage T2, T3, and T4 NSCLC in the reference group, respectively. The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 NSCLC and significantly worse than that of patients with clinical stage T3 NSCLC (p = 0.012). The differences in OS between patients with pIMA and those with clinical stage T3 or T4 NSCLC were not significant (p = 0.11 and p = 0.37, respectively). In patients with pIMA, the presence of separate nodules was a significant factor associated with poor RFS and OS {unadjusted hazard ratio (HR), 4.66 (95% confidence interval [CI], 1.95–11.11), p < 0.001 for RFS; adjusted HR, 4.53 (95% CI, 1.59–12.89), p = 0.005 for OS}. CONCLUSION: The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 lung cancer. Separate nodules on CT were associated with poor RFS and OS in patients with pIMA. The Korean Society of Radiology 2022-03 2022-02-18 /pmc/articles/PMC8876658/ /pubmed/35213098 http://dx.doi.org/10.3348/kjr.2021.0465 Text en Copyright © 2022 The Korean Society of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thoracic Imaging
Kim, Wooil
Lee, Sang Min
Lee, Jung Bok
Seo, Joon Beom
Kim, Hong Kwan
Kim, Jhingook
Lee, Ho Yun
Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
title Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
title_full Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
title_fullStr Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
title_full_unstemmed Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
title_short Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
title_sort prognosis for pneumonic-type invasive mucinous adenocarcinoma in a single lobe on ct: is it reasonable to designate it as clinical t3?
topic Thoracic Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876658/
https://www.ncbi.nlm.nih.gov/pubmed/35213098
http://dx.doi.org/10.3348/kjr.2021.0465
work_keys_str_mv AT kimwooil prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3
AT leesangmin prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3
AT leejungbok prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3
AT seojoonbeom prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3
AT kimhongkwan prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3
AT kimjhingook prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3
AT leehoyun prognosisforpneumonictypeinvasivemucinousadenocarcinomainasinglelobeonctisitreasonabletodesignateitasclinicalt3